Daiichi, Eisai Look Beyond Japan To Expanded Markets In Southeast Asia (Japan)
This article was originally published in PharmAsia News
Daiichi Sankyo and Eisai are reaching beyond their Japan bases into other Asian markets to seek faster growth than they are seeing at home. Daiichi is looking to India as a good market for some of its flagship products, beginning in the spring, and is hiring a 100-person sales force, but Taiwan and other Asian markets also are in Daiichi plans. Eisai plans drug trials in China where it hopes to tap into a huge market, beginning with one for hepatitis B. Also in Eisai plans are member countries of the Association of Southeast Asian Nations where Eisai is looking for a 20 percent annual sales increase. (Click here for more - may require a subscription
You may also be interested in...
NEW DELHI - Faced with margin pressures elsewhere, pharmaceutical multinationals have been eyeing the burgeoning Indian market ever since the country signed the Trade-Related Aspects of Intellectual Property Rights pact. Initially hesitant, Japanese pharma companies are now following in the footsteps of Western companies, using India as a hub for low-cost contract manufacturing and clinical trials
Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.